Simple determination and quantification of tofacitinib, a JAK inhibitor, in rat plasma, urine and tissue homogenates by HPLC and its application to a pharmacokinetic study

다국어 초록 (Multilingual Abstract)

Purpose Tofacitinib, a janus kinase (JAK) inhibitor, was developed for the treatment of rheumatoid arthritis. To evaluate its pharmacokinetic characteristics, a simple method of quantifying tofacitinib by high-performance liquid chromatography (HPLC) was developed to estimate its concentrations in rat plasma, urine and tissue homogenates.
Methods Hydrocortisone was used as an internal standard. The mobile phase was an isocratic system of acetonitrile: 10 mM ammonium acetate, pH 5.0 (30.5:69.5, v/v), and the flow rate was 1.0 mL/min. Chromatograms were monitored by a UV detector at 287 nm. The retention times for tofacitinib and hydrocortisone were 7.21 and 11.3 min, respectively.
Results The lower limits of quantification for tofacitinib in rat plasma and urine were 0.01 and 0.1 μg/mL, respectively. The intraday assay precisions (coefficients of variation) were generally low; 3.69–5.88% for rat plasma and 4.21–6.18% for rat urine. The corresponding values of interday assay precisions were 5.06% and 5.46%, respectively. Accuracies ranged from 92.9 to 107%, with no interference by endogenous substances. Tofacitinib has a short half-life (39.0 min) and was widely distributed in rat tissues.
Conclusion This HPLC method is very simple and sensitive and can be applied to future preclinical and clinical investigations of tofacitinib.

참고문헌 (Reference)

1 Dowty ME, "The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans" 42 : 759-773, 2014

2 Kim SH, "Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative" 20 : 355-360, 1999

3 Govind S, "Stability indicating HPLC method for the quantification of tofacitinib citrate and its related substances" 6 : 11-19, 2014

4 Paniagua R, "Quantitative analysis of the immunosuppressant CP-690, 550 in whole blood by column-switching high-performance liquid chromatography and mass spectrometry detection" 27 : 608-616, 2005

5 Dowty ME, "Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis" 348 : 165-173, 2014

6 Eun Sin Du, "Pharmacokinetics of YJC-10592, a novel chemokine receptor 2 (CCR-2) antagonist, in rats" 대한약학회 39 (39): 833-842, 2016

7 Kim SH, "Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition" 21 : 1-17, 1993

8 Gibaldi M, "Pharmacokinetics" Marcel-Dckker 1982

9 Antonelli E, "Novel oral-targeted therapies for mucosal healing in ulcerative colitis" 24 : 5322-5330, 2018

10 Boor PPC, "JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa" 188 : 67-79, 2017

11 Martina MN, "Inhibition of JAK3 and PKC via immunosuppressive drugs tofacitinib and sotrastaurin inhibits proliferation of human B lymphocytes" 48 : 3046-3052, 2016

12 CDER, "Guidance for industry: bioanalytical methods validation"

13 Shin WG, "Factors influencing the protein binding of vancomycin" 12 : 637-646, 1991

14 Harnett J, "Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept and abatacept in ra patients with previous biologic DMARD: data from a U.S. administrative claims database" 22 : 1457-1471, 2016

15 Lee JS, "Dose-dependent pharmacokinetics of tofacitinib in rats : influence of hepatic and intestinal first-pass metabolism" 11 : E318-, 2019

16 Nag S, "Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b] indole anticancer agent, and an initial pharmacokinetic study in mice" 29 : 654-663, 2015

17 Vijay Kumar S, "Development and validation of a RP HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study" 29 : 1325-1329, 2015

18 Kim SH, "Determination of a new isoquinolinedione derivative, 7-anilino-5, 8-isoquinolinedione, in plasma, urine and tissue homogenates by high-performance liquid chromatography" 30 : 519-526, 2002

19 Tomohiro Fukuda, "Current new challenges in the management of ulcerative colitis" 대한장연구학회 17 (17): 36-44, 2019

20 Øie S, "Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer" 71 : 127-128, 1982

21 Sharma K, "A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma : application to a pharmacokinetic study" 29 : 722-732, 2014